Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Simplified Geriatric Assessment-Albumin: The Modified Tool for Older Diffuse Large B-Cell Lymphoma in China

Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Shuai Zhang, Qingyun Cao, Xiaoxuan Xue, Hongmei Jing, Hui Liu

Blood (2023) 142 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2023-184522

Published: 2023

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2023-184348

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

1q21+ Is Associated with Poor Prognosis in Newly Diagnosed Multiple Myeloma Patients with Extramedullary Disease: A Retrospective Study

Shuang Gao, Fei Dong, Ping Yang, Yingtong Chen, Yanfang Wang, Jing Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 6685.

https://doi.org/10.1182/blood-2023-184339

Published: 2023

Journal Articles

Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma

Chunyuan Li, Jingjing Yin, Yue Yuan, Ping Yang, Hui Liu, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2023-181497

Published: 2023

Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2023-180485

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

Blood (2023) 142 (Supplement 1): 1207.

https://doi.org/10.1182/blood-2023-181622

Published: 2023

Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Blood (2023) 142 (Supplement 1): 1900.

https://doi.org/10.1182/blood-2023-183071

Published: 2023

Journal Articles

The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Hongmei Jing

Blood (2023) 142 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2023-184372

Published: 2023

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Yuqin Song, Keshu Zhou, Hongmei Jing, Jianqiu Wu, Haiyan Yang, Yu Bai, Ke Fang, Ziyi Liu, Jun Zhu, Chan Y. Cheah

Blood (2023) 142 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2023-185270

Published: 2023

Journal Articles

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Xiaoyan Ke, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2023-183096

Published: 2023

Journal Articles

Overexpression of Integrin β7 in Newly Diagnosed Multiple Myeloma with High Risk Cytogenetic Abnormality and Poorer Prognosis

Dong Zheng, Wenli Wan, Mingxia Zhu, Hongmei Jing

Blood (2023) 142 (Supplement 1): 6577.

https://doi.org/10.1182/blood-2023-184329

Published: 2023

Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2023-182812

Published: 2023

Journal Articles

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Junyuan Qi, Lin Song, Xudong Wei, Zhimin Zhai, Anyou Wang, Daozi Jiang, Yang Liang, Fei Li, Zhongxing Jiang, Xuejun Zhang, Qunyi Guo, Hongmei Jing, Yajing Xu, Xiangmin Tong, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2023-183088

Published: 2023

Journal Articles

High IL-10 Expression Is Associated with Poor Prognosis in Primary Gastrointestinal Lymphoma

Lingli Wang, Lan Ma, Jinjie Gao, Wei Wan, Ping Yang, Mingxia Zhu, Fei Dong, Hongmei Jing

Blood (2023) 142 (Supplement 1): 6264.

https://doi.org/10.1182/blood-2023-181473

Published: 2023

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao

Blood (2023) 142 (Supplement 1): 6928.

https://doi.org/10.1182/blood-2023-181351

Published: 2023

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients： the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Shaoling Wu, Lijun Mu, Hai Lin, Hebing Zhou, Hong-Xia Shi, Jinghua Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2023-188037

Published: 2023

Journal Articles

Evaluating Chatgpt As an Adjunct for Analyzing Challenging Case

Xiaoni Liu, Ying Song, Hai Lin, Yiying Xu, Chao Chen, Changjian Yan, Xiaoliang Yuan, Fang Bao, Hongmei Jing, Chaoling Wu, Weilong Zhang

Blood (2023) 142 (Supplement 1): 7273.

https://doi.org/10.1182/blood-2023-181518

Published: 2023

NARROW

Simplified Geriatric Assessment-Albumin: The Modified Tool for Older Diffuse Large B-Cell Lymphoma in China

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

1q21+ Is Associated with Poor Prognosis in Newly Diagnosed Multiple Myeloma Patients with Extramedullary Disease: A Retrospective Study

Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Baricitinib in Combination with High-Dose Dexamethasone As First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Overexpression of Integrin β7 in Newly Diagnosed Multiple Myeloma with High Risk Cytogenetic Abnormality and Poorer Prognosis

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

High IL-10 Expression Is Associated with Poor Prognosis in Primary Gastrointestinal Lymphoma

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients： the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Evaluating Chatgpt As an Adjunct for Analyzing Challenging Case

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only